We serve Chemical Name:3,6-THIOXANTHENEDIAMINE-10,10-DIOXIDE CAS:10215-25-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3,6-THIOXANTHENEDIAMINE-10,10-DIOXIDE
CAS.NO:10215-25-5
Synonyms:10,10-dioxo-9H-thioxanthene-3,6-diamine;EINECS 233-527-1
Molecular Formula:C13H12N2O2S
Molecular Weight:260.31200
HS Code:2934999090
Physical and Chemical Properties:
Melting point:213-215ºC
Boiling point:570.3ºC at 760mmHg
Density:1.468g/cm3
Index of Refraction:1.721
PSA:94.56000
Exact Mass:260.06200
LogP:3.83120
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 10,10-dioxo-9H-thioxanthene-3,6-diamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 233-527-1 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,10,10-dioxo-9H-thioxanthene-3,6-diamine Use and application,EINECS 233-527-1 technical grade,usp/ep/jp grade.
Related News: Brian McNamara, currently head of GSK’s consumer healthcare division, will continue to serve as the franchise’s CEO after it breaks away from GSK in 2022, the British pharma said Thursday. 2-ethoxy-2-methyl-5-(trityloxymethyl)-5,6,7,7a-tetrahydro-3aH-[1,3]dioxolo[4,5-b]pyran-6,7-diol manufacturers In Massachusetts, where the bulk of Takeda’s U.S. operations are based since the Shire buyout, the Japanese pharma has been swiftly ramping up its cell therapy ambitions. In September, the company cut the ribbon on a new 24,000-square-foot R&D manufacturing center in Boston, which it said at the time would handle clinical development for three ongoing pipeline programs and two other prospects pegged to enter clinical development by the end of 2021. ethyl 3′-bromo-5′-fluoro-2′-hydroxy-5-oxo-3-(pyridin-2-yl)-2,3,4,5-tetrahydro-[1,1′-biphenyl]-4-carboxylate suppliers As Natural Capsules did not have access to this manufacturing technology, its R&D centre, which is DSIR approved, had started working on the same since 2018, and has now successfully developed the process including fermentation and chemical synthesis steps, Sunil Mundra, managing director, Natural Capsules told Pharmabiz. 2,5-Diphenyl-[1,3]thiazine-6-thione vendor & factory Brian McNamara, currently head of GSK’s consumer healthcare division, will continue to serve as the franchise’s CEO after it breaks away from GSK in 2022, the British pharma said Thursday.,providing support for flexible, cross-sector training programmes to encourage more movement and collaboration between academia, industry and the charity sector
